today announced that it has completed patient enrollment in its DESSOLVE II CE Mark clinical study of the MiStent Drug-Eluting Coronary Stent
Now available in the UK, and implanted for the first time in Europe at Southampton General Hospital, the Resolute Integrity Stent System features a novel drug-eluting coronary stent
with superior deliverability - the ability of the device to traverse the patient's vasculature and reach the blockage in the heart artery.
About three-quarters underwent an elective stenting procedure, and slightly more than half received a drug-eluting coronary stent
has received regulatory approval from Health Canada's Therapeutic Products Directorate (TPD) for use of the Endeavor drug-eluting coronary stent
(DES) system in the treatment of coronary artery disease.
Successful management of patients with a drug-eluting coronary stent
presenting for elective, non-cardiac surgery.
commercialization of its ZoMaxx(TM) Drug-Eluting Coronary Stent
Incorporating Guidant's latest delivery technology promises to improve our current product line and give us entry into the next generation of drug-eluting coronary stent
systems earlier than originally anticipated.
DIRECT II is a prospective, randomized, multi-center clinical study comparing the safety and efficacy of the Svelte drug-eluting coronary stent
Integrated Delivery System (IDS) to Medtronic's Resolute Integrity[TM] drug-eluting stent.
today announced that it has completed its review of the scheduled four-month follow-up on the first 10 patients from the DESSOLVE I first-in-human trial of the MiStent Drug-Eluting Coronary Stent
System ("MiStent DES"), an ultra-thin drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating formulation.
The review included 5,342 patients at Prairie Heart who received their first drug-eluting coronary stent
during May 2003--December 2006.
The TAXUS Liberte stent is currently the market-leading drug-eluting coronary stent
system outside the U.
Abbott (NYSE: ABT) today announced that it will present new data from its SPIRIT family of clinical trials studying the XIENCE(TM) V Everolimus Eluting Coronary Stent System, and the ABSORB trial of the world's first fully bioabsorbable drug-eluting coronary stent
, at the EuroPCR meeting May 22-25 in Barcelona, Spain.